Levetiracetam Tarbis Farma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action reduces neuronal hyper‑excitability and limits the spread of epileptic discharges, thereby providing seizure control.

The dosage of Levetiracetam Tarbis Farma is individualized. A qualified prescriber determines the appropriate dose based on the patient’s age, weight, renal function, and seizure type. Patients should follow the prescribing information provided by their healthcare professional.

Safety data in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should discuss potential exposure with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older agents such as carbamazepine or valproate, levetiracetam has a relatively favorable drug‑interaction profile and does not require routine therapeutic drug monitoring. However, individual response varies, and clinicians choose therapy based on seizure type, comorbidities and tolerability.

Store the tablets at ambient temperature, below 25 °C, in the original blister pack or container. Protect from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Levetiracetam Tarbis Farma is taken orally, usually with water. Tablets can be swallowed whole with or without food. The prescribing physician will advise the exact dosing schedule, which may be once or twice daily depending on the individual treatment plan.

Serious adverse events, although rare, include severe allergic reactions such as Stevens‑Johnson syndrome, suicidal ideation or behavior, significant blood count abnormalities, and hepatic dysfunction. Patients should seek immediate medical attention if they experience rash, mood changes, jaundice or unexplained fatigue.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications listed under major interactions.